Ashutosh K. Tewari, MD

home / authors / ashutosh-k-tewari-md

Articles

Ashutosh K. Tewari, MD

Dr. Tewari on the Factors to Consider for Robotic Radical Prostatectomy in Prostate Cancer

Ashutosh K. Tewari, MD
February 16th 2022

Ashutosh K. Tewari, MD, discusses the factors to consider when deciding on a robotic radical prostatectomy​ for a patient with prostate cancer.

Read More

Ashutosh K. Tewari, MD

Dr. Tewari on the Benefits of Robotic Radical Prostatectom​y​ in Prostate Cancer

Ashutosh K. Tewari, MD
September 10th 2021

Ashutosh K. Tewari, MD, discusses the benefits of robotic radical prostatectom​y in prostate cancer.

Read More

Ashutosh K. Tewari, MD, of Mount Sinai

Dr. Tewari on Key Differences Between Racial Subgroups in Prostate Cancer

Ashutosh K. Tewari, MD
April 23rd 2021

Ashutosh K. Tewari, MD, discusses some of the key differences between racial subgroups in prostate cancer.

Read More

Ashutosh K. Tewari, MD, of Mount Sinai

Dr. Tewari on the Hallmarks of Cancer in Black Men With Prostate Cancer

Ashutosh K. Tewari, MD
April 22nd 2021

Ashutosh K. Tewari, MD, discusses the hallmarks of cancer among Black men with prostate cancer.

Read More

Ashutosh K. Tewari, MD, of Mount Sinai

Dr. Tewari on the Potential Benefits of a Mobile MRI Unit in Prostate Cancer

Ashutosh K. Tewari, MD
April 21st 2021

Ashutosh K. Tewari, MD, director, Department of Urology, Mount Sinai, discusses the potential benefits of a mobile MRI unit in prostate cancer.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need